Development and Evaluation of Lactose-Free Single-Unit and Multiple-Unit Preparations of a BCS Class II Drug, Rivaroxaban

Development and Evaluation of Lactose-Free Single-Unit and Multiple-Unit Preparations of a BCS Class II Drug, Rivaroxaban

<b>Background/Objectives</b>: The aim of the present study was to develop lactose-free formulations of rivaroxaban, a novel oral anticoagulant used for the treatment and prevention of blood clotting. As a BCS Class II drug, rivaroxaban is characterized by poor solubility in aqueous media...

Full description

Saved in:
Bibliographic Details
Main Authors: Daniel Zakowiecki (Author), Peter Edinger (Author), Markos Papaioannou (Author), Michael Wagner (Author), Tobias Hess (Author), Jadwiga Paszkowska (Author), Marcela Staniszewska (Author), Daria Myslitska (Author), Michal Smolenski (Author), Justyna Dobosz (Author), Grzegorz Garbacz (Author), Dorota Haznar Garbacz (Author)
Format: Book
Published: MDPI AG, 2024-11-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items